AstraZeneca's Truqap Achieves Phase III Success in Prostate Cancer After Initial Setback

AstraZeneca's Truqap has achieved a significant milestone with its success in the Phase III CAPItello-281 trial for prostate cancer. As an AKT inhibitor, Truqap demonstrated enhanced radiographic progression-free survival (rPFS) when used in combination with abiraterone and androgen deprivation therapy (ADT) in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer. This marks it as the first AKT inhibitor to show benefits in this patient group, setting it apart in the prostate cancer treatment landscape[1][2]. While the overall survival data remains immature, early indications are promising for life extension, and AstraZeneca plans to present these findings at an upcoming medical congress. This achievement is particularly notable following the drug's previous failure in a breast cancer study[1][2].